- Investing Ideas
- /
- German Undervalued Stocks Based On Cash Flows
German Undervalued Stocks Based On Cash Flows
Results
29
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
29 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
PSAN | €21.90 | 3.8% | -31.3% | €340.7m | €30.18 | PS1.3x | E59.8% | 1.8% | Software | ||
CHG | €23.80 | 0.8% | 63.0% | €428.3m | €27.00 | PS6.1x | E73.4% | n/a | Healthcare | ||
RDC | €108.20 | -9.6% | 9.1% | €2.3b | €148.83 | PS1.1x | E48.7% | n/a | Consumer Retailing | ||
RTV | €2.40 | 0% | -9.8% | €36.7m | €2.80 | PS13x | E116.8% | n/a | Media | ||
NVM | €5.50 | -2.1% | -47.6% | €234.9m | €12.45 | PE6.8x | E28.1% | 7.3% | Automobiles | ||
STM | €43.50 | -1.0% | -20.3% | €1.1b | €63.44 | PE14.6x | E20.5% | 4.0% | Capital Goods | ||
SBS | €45.60 | -1.1% | -27.7% | €557.3m | €42.33 | PE45.6x | E21.9% | 1.2% | Healthcare | ||
SANT | €19.26 | -0.4% | -1.5% | €1.2b | €30.28 | PE15.9x | E21.0% | 2.6% | Software | ||
MTX | €244.60 | 10.8% | 5.6% | €12.7b | €246.19 | PS2.4x | E35.5% | 0.8% | Capital Goods | ||
CY1K | €3.48 | 10.8% | -48.1% | €33.6m | €7.00 | PB1x | E102.7% | n/a | Capital Goods | ||
TTR1 | €17.75 | -8.0% | -30.4% | €122.3m | €21.50 | PE19.2x | E29.4% | 3.5% | Capital Goods | ||
ADS | €216.00 | -0.9% | 20.9% | €39.2b | €224.08 | PE453.7x | E41.3% | 0.3% | Consumer Durables | ||
SAP | €185.20 | 1.9% | 50.1% | €215.2b | €192.00 | PE83.3x | E33.8% | 1.2% | Software | ||
RSL2 | €19.20 | -5.9% | -15.0% | €124.3m | €30.00 | PB1.8x | E58.9% | 0% | Capital Goods | ||
AEIN | €18.35 | -0.8% | -26.3% | €210.0m | €32.63 | PE15.7x | E25.2% | 2.7% | Software | ||
E4C | €14.05 | -3.1% | -34.0% | €49.3m | €40.50 | PE32.6x | E46.7% | 3.3% | Telecom | ||
V3S | €10.70 | 0% | 136.2% | €86.2m | €10.25 | PS2.3x | E123.1% | 0% | Tech | ||
ISHA | €2.02 | 1.0% | -6.9% | €29.5m | €2.60 | PB2.6x | E80.5% | n/a | Software | ||
R3NK | €26.01 | -2.0% | n/a | €2.6b | €31.88 | PE82.6x | E33.4% | 1.2% | Capital Goods | ||
BSL | €10.60 | -2.8% | -37.5% | €330.1m | €15.70 | PS1.7x | E84.0% | 0% | Tech | ||
EQS | €39.40 | 0% | 90.3% | €394.9m | €37.50 | PS5.5x | E115.5% | 0% | Software | ||
GXI | €99.25 | 2.4% | -7.5% | €3.5b | €134.82 | PE29.3x | E20.4% | 1.3% | Pharmaceuticals & Biotech | ||
SJJ | €11.80 | -4.8% | 37.2% | €126.0m | €19.75 | PS1.3x | E111.5% | 0% | Software | ||
ST5 | €29.35 | -4.2% | -5.3% | €408.4m | €39.50 | PE24.5x | E21.1% | 0% | Capital Goods |